Despite recent gains, market expectations were higher, leadi...
Despite recent gains, market expectations were higher, leading to a share price decline over three years. Future may brighten due to revenue trends, but caution advised based on Kangmei Pharmaceutical's analysis.
Kangmei Pharmaceutical (SHSE:600518 Investor Three-year Losses Grow to 49% as the Stock Sheds CN¥1.2b This Past Week
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment